Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Prospective, Randomized, Controlled Study Evaluating EVICEL® Fibrin Sealant as an Adjunct to Haemostasis During Abdominal, Retroperitoneal, Pelvic or Thoracic (Non-Cardiac) Surgery in Paediatric Patients

    Summary
    EudraCT number
    2013-003401-26
    Trial protocol
    GB   BE  
    Global end of trial date
    17 May 2019

    Results information
    Results version number
    v1(current)
    This version publication date
    03 Dec 2019
    First version publication date
    03 Dec 2019
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    400-12-006
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02227706
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    ETHICON Inc
    Sponsor organisation address
    Route 22 West, Somerville, United States, 08876-0262
    Public contact
    Leonie Rynn, ETHICON Inc, 001 9082182492, lrynn1@its.jnj.com
    Scientific contact
    Leonie Rynn, ETHICON Inc, 001 9082182492, lrynn1@its.jnj.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-001149-PIP01-11
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    22 Jul 2019
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    17 May 2019
    Global end of trial reached?
    Yes
    Global end of trial date
    17 May 2019
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the safety and effectiveness of EVICEL® as an adjunct to achieve haemostasis during surgery in paediatric patients.
    Protection of trial subjects
    Study information was presented to the patient and their legal guardian by a trained member of the research team. The final taking of informed consent was completed by the Investigator or sub−investigator when the potential participant and their legal guardian were completely satisfied with the information presented. Venepuncture was required, however we minimised the number required and where possible results that were already available were used rather than repeating the test. All visits were conducted at times where the patient would routinely attend the hospital with the option to conduct the 30 day follow-up visit by telephone. Physical examinations were undertaken by a trained member of the research team in a private area or room, or if this procedure was completed routinely upon admission to the hospital it was not repeated. The study was reviewed and approved by the respective ethics committees in the countries where the study was being conducted.
    Background therapy
    None.
    Evidence for comparator
    With a clinical history spanning more than 50 years, SURGICEL® has been used as an adjunct to achieve and accelerate haemostasis when various types of bleeding were observed intra-operatively. The product can be placed on the source of bleeding with manual compression to facilitate haemostasis and was therefore considered a suitable control product for use in this study.
    Actual start date of recruitment
    05 Nov 2014
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Canada: 4
    Country: Number of subjects enrolled
    United Kingdom: 36
    Worldwide total number of subjects
    40
    EEA total number of subjects
    36
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    7
    Children (2-11 years)
    13
    Adolescents (12-17 years)
    20
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The first subject was recruited on 5th November 2014 and the last subject was recruited on 17th April 2019. The last subject's last visit took place on 17th May 2019.

    Pre-assignment
    Screening details
    Prospective subjects were screened within 21 days prior to surgery. Prior to any study related procedures, subjects and/or parent or legal representative were fully informed of all aspects of the study. Subjects and/or their parent or legal representative were asked to sign a Consent Form or assent, as applicable.

    Period 1
    Period 1 title
    Full Analysis Set (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded
    Blinding implementation details
    N/A

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    EVICEL®
    Arm description
    EVICEL® is a human plasma derived fibrin sealant consisting of two components: (1) Biologically Active Component 2 (BAC2), a concentrate of human clottable protein (containing mainly human fibrinogen and fribrinectin), and (2) human thrombin.
    Arm type
    Experimental

    Investigational medicinal product name
    EVICEL®
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for sealant
    Routes of administration
    Epilesional use
    Dosage and administration details
    For each subject, at least one EVICEL® (BAC2 and Thrombin) kit was thawed and available for administration prior to randomization. EVICEL® was to be sprayed or dripped onto the tissue to produce a thin, even layer.

    Arm title
    SURGICEL®
    Arm description
    SURGICEL® Absorbable hemostat is a sterile absorbable knitted fabric prepared by controlled oxidation of regenerated cellulose.
    Arm type
    Active comparator

    Investigational medicinal product name
    SURGICEL® Original
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Sealant matrix
    Routes of administration
    Topical use
    Dosage and administration details
    For subjects randomized to SURGICEL®, the product was to be applied and held firmly on the TBS, immediately after randomization according to the product instructions for use.

    Number of subjects in period 1
    EVICEL® SURGICEL®
    Started
    20
    20
    Completed
    20
    20

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    EVICEL®
    Reporting group description
    EVICEL® is a human plasma derived fibrin sealant consisting of two components: (1) Biologically Active Component 2 (BAC2), a concentrate of human clottable protein (containing mainly human fibrinogen and fribrinectin), and (2) human thrombin.

    Reporting group title
    SURGICEL®
    Reporting group description
    SURGICEL® Absorbable hemostat is a sterile absorbable knitted fabric prepared by controlled oxidation of regenerated cellulose.

    Reporting group values
    EVICEL® SURGICEL® Total
    Number of subjects
    20 20 40
    Age Categorical
    Units: Subjects
        Infants and toddlers (28 days-23 months)
    5 2 7
        Children (2-11 years)
    4 9 13
        Adolescents (12-17 years)
    11 9 20
    Age Continuous
    Units: years
        arithmetic mean (full range (min-max))
    9.4 (0.9 to 17.0) 9.0 (1.0 to 17.0) -
    Gender Categorical
    Units: Subjects
        Female
    11 7 18
        Male
    9 13 22
    Subject analysis sets

    Subject analysis set title
    Full Analysis Set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All randomised subjects

    Subject analysis set title
    Per Protocol
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Full analysis set who had no major protocol deviations

    Subject analysis set title
    Safety Set
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All subjects who received treatment

    Subject analysis sets values
    Full Analysis Set Per Protocol Safety Set
    Number of subjects
    40
    38
    40
    Age Categorical
    Units: Subjects
        Infants and toddlers (28 days-23 months)
    7
    7
    7
        Children (2-11 years)
    13
    13
    13
        Adolescents (12-17 years)
    20
    18
    20
    Age Continuous
    Units: years
        arithmetic mean (full range (min-max))
    9.2 (0.9 to 17.0)
    8.9 (0.9 to 17.0)
    9.2 (0.9 to 17.0)
    Gender Categorical
    Units: Subjects
        Female
    18
    18
    18
        Male
    22
    20
    22

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    EVICEL®
    Reporting group description
    EVICEL® is a human plasma derived fibrin sealant consisting of two components: (1) Biologically Active Component 2 (BAC2), a concentrate of human clottable protein (containing mainly human fibrinogen and fribrinectin), and (2) human thrombin.

    Reporting group title
    SURGICEL®
    Reporting group description
    SURGICEL® Absorbable hemostat is a sterile absorbable knitted fabric prepared by controlled oxidation of regenerated cellulose.

    Subject analysis set title
    Full Analysis Set
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All randomised subjects

    Subject analysis set title
    Per Protocol
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Full analysis set who had no major protocol deviations

    Subject analysis set title
    Safety Set
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All subjects who received treatment

    Primary: Absolute Time to Haemostasis

    Close Top of page
    End point title
    Absolute Time to Haemostasis [1]
    End point description
    Absolute time to haemostasis, defined as absolute time when there was no detectable bleeding at the Target Bleeding Site (TBS)
    End point type
    Primary
    End point timeframe
    From randomisation
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The primary effectiveness endpoint is summarized descriptively by treatment group.
    End point values
    EVICEL® SURGICEL®
    Number of subjects analysed
    20
    20
    Units: Minutes
    median (confidence interval 95%)
        Absolute time to haemostasis
    4.0 (3.3 to 4.7)
    4.0 (2.9 to 8.1)
    No statistical analyses for this end point

    Secondary: Haemostasis at Target Bleeding Site at 4 Minutes

    Close Top of page
    End point title
    Haemostasis at Target Bleeding Site at 4 Minutes
    End point description
    Haemostasis at 4 Minutes
    End point type
    Secondary
    End point timeframe
    Intra-operatively from randomisation to 4 minutes after randomisation
    End point values
    EVICEL® SURGICEL® Full Analysis Set
    Number of subjects analysed
    20
    20
    40
    Units: Subject
        Haemostasis at 4 Minutes
    16
    13
    29
    No statistical analyses for this end point

    Secondary: Haemostasis at Target Bleeding Site at 7 Minutes

    Close Top of page
    End point title
    Haemostasis at Target Bleeding Site at 7 Minutes
    End point description
    Haemostasis at 7 Minutes
    End point type
    Secondary
    End point timeframe
    Intra-operatively from randomisation to 7 minutes after randomisation
    End point values
    EVICEL® SURGICEL® Full Analysis Set
    Number of subjects analysed
    20
    20
    40
    Units: Subject
        Haemostasis at 7 Minutes
    20
    16
    36
    No statistical analyses for this end point

    Secondary: Haemostasis at Target Bleeding Site at 10 Minutes

    Close Top of page
    End point title
    Haemostasis at Target Bleeding Site at 10 Minutes
    End point description
    Haemostasis at 10 Minutes
    End point type
    Secondary
    End point timeframe
    Intra-operatively from randomisation to 10 minutes after randomisation
    End point values
    EVICEL® SURGICEL® Full Analysis Set
    Number of subjects analysed
    20
    20
    40
    Units: Subject
        Haemostasis at 10 Minutes
    19
    18
    37
    No statistical analyses for this end point

    Secondary: Incidence of Treatment Failures

    Close Top of page
    End point title
    Incidence of Treatment Failures
    End point description
    Defined as haemostasis not achieved within 10 minutes or bleeding requiring treatment other than re-application of the assigned haemostatic adjunct within 10 minutes.
    End point type
    Secondary
    End point timeframe
    10 minutes
    End point values
    EVICEL® SURGICEL®
    Number of subjects analysed
    20
    20
    Units: Number of subjects (failure)
    1
    5
    No statistical analyses for this end point

    Other pre-specified: Number of Subjects with a Thrombotic Event

    Close Top of page
    End point title
    Number of Subjects with a Thrombotic Event
    End point description
    End point type
    Other pre-specified
    End point timeframe
    From randomisation up to 30 days (+/- 14 days) following surgery
    End point values
    EVICEL® SURGICEL®
    Number of subjects analysed
    20
    20
    Units: Subjects
        Number of subjects with thrombotic events
    0
    0
    No statistical analyses for this end point

    Other pre-specified: Number of Subjects with an Adverse Event Related to Re-bleeding at Target Bleeding Site

    Close Top of page
    End point title
    Number of Subjects with an Adverse Event Related to Re-bleeding at Target Bleeding Site
    End point description
    End point type
    Other pre-specified
    End point timeframe
    From randomisation to 30 days (+/- 14 days) following surgery
    End point values
    EVICEL® SURGICEL®
    Number of subjects analysed
    20
    20
    Units: Subject
        Subjects with AE related to re-bleeding at TBS
    1
    2
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse Events were collected from point of randomisation, during the procedure, throughout hospital admission and until completion of the 30 day (+/-14 day) follow up visit.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    16.0
    Reporting groups
    Reporting group title
    EVICEL®
    Reporting group description
    EVICEL® is a human plasma derived fibrin sealant consisting of two components: (1) Biologically Active Component 2 (BAC2), a concentrate of human clottable protein (containing mainly human fibrinogen and fribrinectin), and (2) human thrombin.

    Reporting group title
    SURGICEL®
    Reporting group description
    SURGICEL® Absorbable hemostat is a sterile absorbable knitted fabric prepared by controlled oxidation of regenerated cellulose.

    Serious adverse events
    EVICEL® SURGICEL®
    Total subjects affected by serious adverse events
         subjects affected / exposed
    4 / 20 (20.00%)
    3 / 20 (15.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Castleman's disease
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Procedural complication
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Surgical and medical procedures
    Ureteral stent removal
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Brain Injury
    Additional description: Hypoxic Brain Injury
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Febrile neutropenia
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Urinary incontinence
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Varicella
    Additional description: Chicken Pox
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Clostridium difficile infection
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    EVICEL® SURGICEL®
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    18 / 20 (90.00%)
    20 / 20 (100.00%)
    Vascular disorders
    Haemorrhage
         subjects affected / exposed
    1 / 20 (5.00%)
    2 / 20 (10.00%)
         occurrences all number
    1
    2
    Hypertension
         subjects affected / exposed
    1 / 20 (5.00%)
    2 / 20 (10.00%)
         occurrences all number
    1
    2
    Hypotension
         subjects affected / exposed
    2 / 20 (10.00%)
    2 / 20 (10.00%)
         occurrences all number
    2
    3
    Surgical and medical procedures
    Wound drainage
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Chest pain
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Device occlusion
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Pain
         subjects affected / exposed
    2 / 20 (10.00%)
    0 / 20 (0.00%)
         occurrences all number
    2
    0
    Pyrexia
         subjects affected / exposed
    8 / 20 (40.00%)
    6 / 20 (30.00%)
         occurrences all number
    9
    7
    Swelling
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Reproductive system and breast disorders
    Testicular pain
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Atelectasis
         subjects affected / exposed
    0 / 20 (0.00%)
    2 / 20 (10.00%)
         occurrences all number
    0
    2
    Cough
         subjects affected / exposed
    1 / 20 (5.00%)
    3 / 20 (15.00%)
         occurrences all number
    1
    3
    Dyspnoea
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Haemoptysis
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Hyperventilation
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Neonatal aspiration
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Pleural effusion
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Pneumothorax
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Respiratory depression
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Tachypnoea
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 20 (5.00%)
         occurrences all number
    1
    1
    Investigations
    Blood potassium decreased
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    C-reactive protein increased
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Haemoglobin decreased
         subjects affected / exposed
    1 / 20 (5.00%)
    2 / 20 (10.00%)
         occurrences all number
    1
    2
    Oxygen saturation decreased
         subjects affected / exposed
    1 / 20 (5.00%)
    2 / 20 (10.00%)
         occurrences all number
    1
    3
    Respiratory rate decreased
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Respiratory rate increased
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Urine output decreased
         subjects affected / exposed
    2 / 20 (10.00%)
    0 / 20 (0.00%)
         occurrences all number
    2
    0
    White blood cell count increased
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Procedural complication
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Procedural pain
         subjects affected / exposed
    7 / 20 (35.00%)
    5 / 20 (25.00%)
         occurrences all number
    8
    5
    Wound complication
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 20 (5.00%)
         occurrences all number
    1
    1
    Wound secretion
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Cardiac disorders
    Bradycardia
         subjects affected / exposed
    0 / 20 (0.00%)
    2 / 20 (10.00%)
         occurrences all number
    0
    2
    Tachycardia
         subjects affected / exposed
    3 / 20 (15.00%)
    6 / 20 (30.00%)
         occurrences all number
    3
    6
    Nervous system disorders
    Convulsion
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Dizziness
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Headache
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Hypoaesthesia
         subjects affected / exposed
    2 / 20 (10.00%)
    0 / 20 (0.00%)
         occurrences all number
    2
    0
    Blood and lymphatic system disorders
    Coagulopathy
         subjects affected / exposed
    2 / 20 (10.00%)
    0 / 20 (0.00%)
         occurrences all number
    2
    0
    Febrile neutropenia
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Eye disorders
    Conjunctivitis
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal disorders
    Abdominal discomfort
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Abdominal distension
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Abdominal pain
         subjects affected / exposed
    5 / 20 (25.00%)
    3 / 20 (15.00%)
         occurrences all number
    5
    3
    Abdominal pain lower
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Abdominal pain upper
         subjects affected / exposed
    0 / 20 (0.00%)
    2 / 20 (10.00%)
         occurrences all number
    0
    2
    Constipation
         subjects affected / exposed
    1 / 20 (5.00%)
    2 / 20 (10.00%)
         occurrences all number
    1
    2
    Diarrhoea
         subjects affected / exposed
    3 / 20 (15.00%)
    4 / 20 (20.00%)
         occurrences all number
    3
    4
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Ileus
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Mucous stools
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Nausea
         subjects affected / exposed
    2 / 20 (10.00%)
    2 / 20 (10.00%)
         occurrences all number
    2
    2
    Teething
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Vomiting
         subjects affected / exposed
    3 / 20 (15.00%)
    6 / 20 (30.00%)
         occurrences all number
    3
    6
    Skin and subcutaneous tissue disorders
    Blister
         subjects affected / exposed
    2 / 20 (10.00%)
    1 / 20 (5.00%)
         occurrences all number
    2
    1
    Decubitus ulcer
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Dermatitis diaper
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Livedo reticularis
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Pruritus
         subjects affected / exposed
    2 / 20 (10.00%)
    1 / 20 (5.00%)
         occurrences all number
    2
    1
    Rash
         subjects affected / exposed
    1 / 20 (5.00%)
    2 / 20 (10.00%)
         occurrences all number
    1
    2
    Rash erythematous
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Erythema
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Renal and urinary disorders
    Polyuria
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Musculoskeletal pain
         subjects affected / exposed
    0 / 20 (0.00%)
    2 / 20 (10.00%)
         occurrences all number
    0
    2
    Infections and infestations
    Candidiasis
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Infection
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Nasopharyngitis
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Orchitis
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Pneumonia
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Post procedural infection
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Urinary tract infection
         subjects affected / exposed
    1 / 20 (5.00%)
    1 / 20 (5.00%)
         occurrences all number
    1
    1
    Viral infection
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Wound infection
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Fluid overload
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Hypoalbuminaemia
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Hyponatraemic syndrome
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences all number
    0
    1
    Hypokalaemia
         subjects affected / exposed
    1 / 20 (5.00%)
    3 / 20 (15.00%)
         occurrences all number
    1
    3
    Metabolic acidosis
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0
    Polydipsia
         subjects affected / exposed
    1 / 20 (5.00%)
    0 / 20 (0.00%)
         occurrences all number
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    02 Oct 2013
    A number of up-dates were made including the following - Product application technique, product labeling and shipping; visit timelines; primary and secondary endpoint clarifications to align with the Paediatric Investigation Plan (PIP); up-dates to the description of the analysis for success/failure data; administrative up-dates
    31 Jul 2015
    A number of up-dates were made including the following - Addition of parenchymal organ bleeding; up-date to the definition of open procedure and infected field; airless spray accessory device added; administrative up-dates
    29 Feb 2016
    A number of up-dates were made including the following - Up-dated to reflect the change in age group specifications for study recruitment; up-dated to further define treatment failure; clarification on statistical analysis for primary and secondary endpoints, laboratory values and handling of missing data; administrative up-dates
    08 Jan 2018
    A number of up-dates were made including the following - Removal of age stratification; further clarification on open procedure definition; additional information on product storage conditions; product application clarifications; administrative up-dates

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Two subjects in the control arm were haemostatic at the TBS at 10 minutes however they subsequently rebled requiring additional treatment and were conservatively considered a failure for the secondary endpoint of Incidence of Treatment Failures.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 10:39:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA